<table>
<thead>
<tr>
<th>Study Title</th>
<th>Description</th>
<th>Key Requirements</th>
<th>Contact</th>
</tr>
</thead>
</table>
| NuvaRing and ART (5316)                         | A study to examine the interaction of the Nuva Ring birth control method and HIV medications in HIV positive women                                                                                                          | Key requirements:  
  - 18 years or older and have HIV  
  - Must be premenopausal and agree to not participate in conception                                                                                                    | Debbie 793-4635 |
| Inflammation & heart health in HIV Study (5314) | A study to look at the effects of low-dose methotrexate on inflammation and heart health in HIV infected adults                                                                                                  | Key requirements:  
  - HIV-1 positive adults 40 or older  
  - Undetectable viral load and a CD4 count 400 or greater  
  - Women cannot be of childbearing potential  
  - Heart disease or at high risk for heart disease                                                                                                         | Pam 793-4971  |
| Inflammation in HIV (5325)                      | A study to see if isotretinoin can repair some of the damaging effects of HIV and inflammation                                                                                                                 | Key requirements:  
  - Men & post-menopausal women 18 to 79 years of age  
  - Currently on HIV medications and non-detectible viral load  
  - No Hep B or C, severe depression or diabetes                                                                                                            | Helen 793-4771 |
| Hep C & HIV co-infection (5329)                 | This is a study to test a new Hep C medication in people with both Hep C and HIV.                                                                                                                                 | Key requirements:  
  - 18 to 70 years of age  
  - Not pregnant or nursing or have a pregnant sexual partner  
  - CD4 count 200 or greater and no prior Hep C treatment                                                                                                  | Pam 793-4971  |
| Drive Forward study Merck 1439 Treatment naïve HIV | This study is to test the safety and effectiveness of an investigational drug vs Darunavir/Ritonavir given with Truvada or Epzicom for HIV                                                                                 | Key requirements:  
  - Are at least 18 years of age  
  - Have been diagnosed with HIV  
  - Have not previously taken any ARTs.                                                                                                           | Pam 793-4971  |
| Drive Ahead study Merck 1439A Treatment naïve HIV | This study is to test the safety and effectiveness of an investigational drug vs Atripla for HIV                                                                                                              | Key requirements:  
  - Are at least 18 years of age  
  - Have been diagnosed with HIV  
  - Have not previously taken any ARTs                                                                                                           | Matt 793-4317 |
| REPRIEVE (5332) HIV/Heart prevention study       | This study is to test if PITAVASTATIN can prevent heart disease and related complications in HIV+ people taking HIV medications                                                                                  | Key requirements:  
  - Between the ages of 40 and 75 with a CD4 count above 100  
  - Currently taking HIV medication and NOT taking a statin  
  - No history of heart disease or stroke                                                                                                           | Helen 793-4771 |
| GS1160 HIV switch study                         | A study to compare the safety and effectiveness of an experimental single tablet containing 2 FDA approved drugs and one investigational drug with Atripla                                                    | Key requirements:  
  - 18 years of age or older and currently on Atripla  
  - Not pregnant or nursing and willing to use highly effective contraception of avoid pregnancy  
  - Viral load less than 50                                                                                                                             | Helen 793-4771 |
| GS1216 HIV switch study                         | A study to compare the safety and effectiveness of an experimental single tablet containing 2 FDA approved drugs and one investigational drug with Complera.                                                    | Key requirements:  
  - 18 years of age or older and currently on Complera  
  - Not pregnant or nursing and willing to use highly effective contraception of avoid pregnancy  
  - Viral load less than 50                                                                                                                             | Pam 793-4971  |
| EMERALD Study HIV switch study                  | A study to evaluate switching to an investigational single tablet medicine with continuation of your current multi-tablet regimen                                                                              | Key requirements:  
  - 18 years of age  
  - Well-controlled on current HIV medication  
  - On the same HIV medication for at least 6 months                                                                                                       | Debbie 793-4635 |